🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementAnyone else get weird vivid dreams on sema??

Anyone else get weird vivid dreams on sema??

SleepFixSam Thu, Apr 2, 2026 at 1:51 AM 5 replies 590 viewsPage 1 of 1
SleepFixSam
Member
212
678
Nov 2024
Hawaii
Apr 2, 2026 at 1:51 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What I actually want to know is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Tell me what I have not thought of.

2 22pete_nash, hank_denver
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Apr 2, 2026 at 2:23 AM#2

This one has a reasonably settled answer, so here it is. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

1 21tyler_CSCS
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Apr 2, 2026 at 2:55 AM#3
Dr.GutHealth said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

No disagreement with Dr.GutHealth. One condition attached. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

50 20Dr.LipidDallas, alex_tucson, kevin_tulsa and 47 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Apr 2, 2026 at 3:28 AM#4
SleepFixSam said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Can confirm the pattern SleepFixSam describes. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Apr 2, 2026 at 9:28 AM
49 19Dr.PainCLE, mike_mealprep, NicoleRaleigh and 46 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Apr 2, 2026 at 6:28 AM#5

Adding the clinical framing, because it changes how the question reads. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

I would rather be corrected than agreed with, if it comes to it.

48 18bbq_ray_KC, oliver_london, tane_welly and 45 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register